Evaluation of Long-Acting Lenacapavir for the Treatment of HIV-1 in Treatment-experienced Adolescents and Children.

The article discusses a clinical trial, NCT06749054, evaluating the use of lenacapavir (LEN) in combination with other medications for adolescents and children with HIV-1 who have been previously treated. The study aims to assess the safety, tolerability, and efficacy of long-acting LEN, both as an injection and an oral pill, in this population. The primary objectives include evaluating the pharmacokinetics and safety of LEN in combination with an optimized background regimen in treatment-experienced pediatric participants with HIV-1. The trial is set to be completed by March 31, 2026, and focuses on key inclusion and exclusion criteria for participants. [Extracted from the article]